SAGAR SINGH - IIT DELHI
Last Activity: 14 Years ago
Dear farrah,
Plenty of drug makers today are thinking small. Real small. In the neverending pursuit of a better route to certain intermediates and active pharmaceutical ingredients (APIs) and more streamlined operations, drug companies are turning to microreactor technology.
Microreactors are essentially small flow channels, or systems of channels, where reactions may occur. Myriad other microchannel devices exist to handle additional unit operations. The concept behind them is not new, but these devices are now cheaper and easier to come by, and many firms are jumping on the micro-bandwagon. They are looking to perform common pharmaceutical reactions—hydrogenations, oxidations, substitutions, even Wittig and Passerini reactions—in miniaturized continuous flow.
Microreactors have several distinct advantages. Due in large part to their high surface-to-volume ratios and small channel dimensions, they are highly efficient for mixing, mass transfer, and heat transfer. These factors can lead to greater selectivity and higher yields. It also makes them attractive for highly exothermic reactions or those involving hazardous materials that would normally generate large amounts of unwanted by-products.
We are all IITians and here to help you in your IIT JEE preparation.
All the best.
If you like this answer please approve it....
win exciting gifts by answering the questions on Discussion Forum
Sagar Singh
B.Tech IIT Delhi